Genmab A/S’s (GMAB) Buy Rating Reiterated at HC Wainwright

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $50.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 88.82% from the stock’s previous close.

Several other equities analysts also recently weighed in on the company. Royal Bank of Canada raised Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. Truist Financial dropped their price target on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, September 9th. Morgan Stanley reissued an “equal weight” rating and set a $31.00 target price on shares of Genmab A/S in a research note on Wednesday, September 11th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Finally, BTIG Research upped their price target on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Genmab A/S presently has a consensus rating of “Hold” and a consensus target price of $45.20.

Genmab A/S Trading Up 1.1 %

Shares of NASDAQ:GMAB opened at $26.48 on Friday. The company has a market cap of $17.51 billion, a PE ratio of 22.07, a price-to-earnings-growth ratio of 0.81 and a beta of 0.99. The stock has a 50 day moving average of $27.30 and a 200 day moving average of $28.01. Genmab A/S has a 12-month low of $24.53 and a 12-month high of $37.97.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The business had revenue of $779.50 million during the quarter, compared to analysts’ expectations of $734.60 million. Equities research analysts predict that Genmab A/S will post 1.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GMAB. Capital International Investors boosted its stake in Genmab A/S by 7.8% in the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after purchasing an additional 315,355 shares in the last quarter. Harding Loevner LP grew its holdings in shares of Genmab A/S by 2.7% during the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock valued at $97,569,000 after buying an additional 85,665 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Genmab A/S by 7.6% during the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after buying an additional 103,859 shares during the last quarter. First Trust Advisors LP increased its position in shares of Genmab A/S by 16.0% in the 4th quarter. First Trust Advisors LP now owns 1,270,095 shares of the company’s stock valued at $40,440,000 after acquiring an additional 175,292 shares during the period. Finally, DDD Partners LLC purchased a new position in Genmab A/S in the 2nd quarter worth $8,860,000. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.